HK1254728A1 - 用於癌症免疫療法的nkg2d-ig融合蛋白 - Google Patents
用於癌症免疫療法的nkg2d-ig融合蛋白Info
- Publication number
- HK1254728A1 HK1254728A1 HK18113739.9A HK18113739A HK1254728A1 HK 1254728 A1 HK1254728 A1 HK 1254728A1 HK 18113739 A HK18113739 A HK 18113739A HK 1254728 A1 HK1254728 A1 HK 1254728A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nkg2d
- fusion protein
- cancer immunotherapy
- immunotherapy
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255016P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/061479 WO2017083612A1 (en) | 2015-11-13 | 2016-11-11 | An nkg2d-ig fusion protein for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1254728A1 true HK1254728A1 (zh) | 2019-07-26 |
Family
ID=58696066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18113739.9A HK1254728A1 (zh) | 2015-11-13 | 2018-10-26 | 用於癌症免疫療法的nkg2d-ig融合蛋白 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10865232B2 (zh) |
| EP (1) | EP3373970A4 (zh) |
| JP (3) | JP7037480B2 (zh) |
| CN (2) | CN108367071B (zh) |
| AU (3) | AU2016353231B2 (zh) |
| CA (1) | CA3004148A1 (zh) |
| HK (1) | HK1254728A1 (zh) |
| WO (1) | WO2017083612A1 (zh) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3004148A1 (en) | 2015-11-13 | 2017-05-18 | Dana-Farber Cancer Institute, Inc. | An nkg2d-ig fusion protein for cancer immunotherapy |
| WO2019127215A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof |
| SG11202101779RA (en) | 2018-08-30 | 2021-03-30 | Hcw Biologics Inc | Multi-chain chimeric polypeptides and uses thereof |
| KR20210069639A (ko) | 2018-08-30 | 2021-06-11 | 에이치씨더블유 바이올로직스, 인크. | 단일-사슬 키메라 폴리펩타이드 및 이의 용도 |
| AU2019328575A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| EP3898974A1 (en) | 2018-12-21 | 2021-10-27 | Onxeo | New conjugated nucleic acid molecules and their uses |
| JP2022537054A (ja) | 2019-06-21 | 2022-08-23 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| US20220332780A1 (en) | 2019-09-10 | 2022-10-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| EP4031566A1 (en) * | 2019-09-18 | 2022-07-27 | Novartis AG | Nkg2d fusion proteins and uses thereof |
| CN115362169A (zh) | 2020-02-11 | 2022-11-18 | Hcw生物科技公司 | 色谱树脂以及其用途 |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| EP4103601A2 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| TW202200618A (zh) * | 2020-03-17 | 2022-01-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| AU2021262794A1 (en) | 2020-04-29 | 2022-11-24 | HCW Biologics, Inc. | Anti-CD26 proteins and uses thereof |
| JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| WO2022235676A1 (en) * | 2021-05-04 | 2022-11-10 | Actinium Pharmaceuticals, Inc. | Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer |
| WO2023111203A1 (en) | 2021-12-16 | 2023-06-22 | Onxeo | New conjugated nucleic acid molecules and their uses |
| WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
| CN116003627A (zh) * | 2022-09-16 | 2023-04-25 | 四川大学华西医院 | NKG2D-NKp46细胞接合器分子及其用途 |
| WO2024097918A1 (en) | 2022-11-04 | 2024-05-10 | Novartis Ag | Nkg2d fusion protein cancer therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69432744T2 (de) | 1993-02-04 | 2004-03-25 | Borean Pharma A/S | Verbessertes verfahren zur rückfaltung der proteine |
| US6627198B2 (en) * | 1997-03-13 | 2003-09-30 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis antigens and their uses |
| EP1194167B1 (en) * | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US6821522B2 (en) | 2001-05-31 | 2004-11-23 | The Regents Of The University Of California | Tumor Therapy |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| KR100919915B1 (ko) | 2004-04-05 | 2009-10-06 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Ｎｋｇ２ｄ의 조절 |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| US20060252096A1 (en) | 2005-04-26 | 2006-11-09 | Glycofi, Inc. | Single chain antibody with cleavable linker |
| EP1909832A4 (en) | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
| WO2007048849A1 (en) | 2005-10-28 | 2007-05-03 | Novo Nordisk A/S | Fusion proteins that bind effector lymphocytes and target cells |
| US7932055B2 (en) | 2006-06-22 | 2011-04-26 | Novo Nordisk A/S | Soluble heterodimeric CD94/NKG2 receptors fusion proteins |
| WO2008036981A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Research, Inc. | Methods for treating mica-related disorders |
| EP2102234A2 (en) | 2006-11-28 | 2009-09-23 | GHC Research Development Corporation | Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain |
| WO2010003118A1 (en) * | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Tgf-b antagonist multi-target binding proteins |
| EP2326346A4 (en) * | 2008-08-20 | 2012-06-13 | Ibc Pharmaceuticals Inc | DOCK-AND-LOCK (DNL) ACCOSTAGE AND LOCK VACCINES FOR CANCER THERAPY |
| US10865233B2 (en) * | 2008-12-18 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | NKG2D-fc for immunotherapy |
| GB0922209D0 (en) * | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| CN102020717B (zh) * | 2010-11-05 | 2012-09-26 | 扬州大学 | 一种增强淋巴细胞靶向杀伤肿瘤的活性因子及其制备方法 |
| WO2014165818A2 (en) * | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
| US20160272707A1 (en) * | 2013-09-11 | 2016-09-22 | Compugen Ltd. | Vstm5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases |
| CN105636982B (zh) * | 2013-09-16 | 2020-06-23 | 健康与环境慕尼黑德国研究中心赫姆霍茨中心（有限责任公司） | 用于治疗hbv感染和相关病症的结合免疫效应细胞表面抗原和hbv抗原的双或多特异性多肽 |
| WO2017083545A1 (en) * | 2015-11-10 | 2017-05-18 | Fred Hutchinson Cancer Research Center | Nkg2d decoys |
| CA3004148A1 (en) | 2015-11-13 | 2017-05-18 | Dana-Farber Cancer Institute, Inc. | An nkg2d-ig fusion protein for cancer immunotherapy |
-
2016
- 2016-11-11 CA CA3004148A patent/CA3004148A1/en active Pending
- 2016-11-11 AU AU2016353231A patent/AU2016353231B2/en active Active
- 2016-11-11 WO PCT/US2016/061479 patent/WO2017083612A1/en active Application Filing
- 2016-11-11 CN CN201680071013.5A patent/CN108367071B/zh active Active
- 2016-11-11 JP JP2018524359A patent/JP7037480B2/ja active Active
- 2016-11-11 CN CN202210469468.XA patent/CN114853907A/zh active Pending
- 2016-11-11 US US15/775,568 patent/US10865232B2/en active Active
- 2016-11-11 EP EP16865061.2A patent/EP3373970A4/en active Pending
-
2018
- 2018-10-26 HK HK18113739.9A patent/HK1254728A1/zh unknown
-
2020
- 2020-10-22 AU AU2020257104A patent/AU2020257104B2/en active Active
- 2020-11-12 US US17/096,768 patent/US11851472B2/en active Active
-
2022
- 2022-03-04 JP JP2022033214A patent/JP7350917B2/ja active Active
- 2022-09-23 AU AU2022235631A patent/AU2022235631A1/en active Pending
-
2023
- 2023-09-13 JP JP2023148458A patent/JP2023175799A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108367071B (zh) | 2022-05-13 |
| JP7037480B2 (ja) | 2022-03-16 |
| CN114853907A (zh) | 2022-08-05 |
| AU2016353231A1 (en) | 2018-05-17 |
| AU2020257104A1 (en) | 2020-11-19 |
| US20180355013A1 (en) | 2018-12-13 |
| JP2022078203A (ja) | 2022-05-24 |
| AU2022235631A1 (en) | 2022-10-20 |
| AU2020257104B2 (en) | 2022-06-30 |
| JP2023175799A (ja) | 2023-12-12 |
| CN108367071A (zh) | 2018-08-03 |
| CA3004148A1 (en) | 2017-05-18 |
| AU2016353231B2 (en) | 2020-08-13 |
| US11851472B2 (en) | 2023-12-26 |
| EP3373970A1 (en) | 2018-09-19 |
| JP7350917B2 (ja) | 2023-09-26 |
| US20210130434A1 (en) | 2021-05-06 |
| US10865232B2 (en) | 2020-12-15 |
| EP3373970A4 (en) | 2019-07-10 |
| WO2017083612A1 (en) | 2017-05-18 |
| JP2018537449A (ja) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254728A1 (zh) | 用於癌症免疫療法的nkg2d-ig融合蛋白 | |
| HK1244019A1 (zh) | 融合蛋白 | |
| ZA201701810B (en) | Sirp-alpha immunoglobulin fusion proteins | |
| GB201509413D0 (en) | Fusion protein | |
| EP3188758C0 (en) | SIRP-ALPHA ANTIBODY FUSION PROTEINS | |
| GB201502305D0 (en) | Protein | |
| HK1232136A1 (zh) | 融合蛋白 | |
| GB201502306D0 (en) | Protein | |
| IL259793A (en) | slc45a2 peptides for immunotherapy | |
| GB201504691D0 (en) | Fusion protein | |
| HK1257177A1 (zh) | 腫瘤免疫治療 | |
| GB201515745D0 (en) | Proteins | |
| GB201511787D0 (en) | Proteins | |
| HK1257937A1 (zh) | 融合蛋白 | |
| EP3139955A4 (en) | Fusion proteins for treating cancer and related methods | |
| EP3247792A4 (en) | Cancer immunotherapy | |
| GB201513033D0 (en) | Proteins | |
| SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
| GB201602850D0 (en) | Fusion proteins | |
| EP3649159C0 (en) | FUSION PROTEIN | |
| GB201712792D0 (en) | Fusion protein | |
| GB201522610D0 (en) | Protein | |
| GB201520021D0 (en) | Fusion polypeptide | |
| GB201515744D0 (en) | Proteins | |
| GB201503778D0 (en) | Proteins |